Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

Clinical trial NCT03311659 · COMPLETED

Trial details

NCT number

NCT03311659

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2018-01-26

Primary completion

2018-08-31

Enrollment

448

View on ClinicalTrials.gov